Investigating Gene and Pathway Association in Type 2 Diabetes, Obesity, and Diabetic Nephropathy: A Network Systems Biology Approach
, 1
Abstract
Objective: The present study aims to identify underlying molecular factors and mechanisms responsible for type 2 diabetes (T2D) to unravel its molecular association with obesity and diabetic nephropathy (DN) using an in silico network systems biology-based integrative approach. Materials and methods: Microarray datasets for T2D, obesity, and DN were retrieved from the Gene Expression Omnibus (GEO) database through GEO query package of R programming language followed by the identification of common differentially expressed genes (DEGs) in the 3 diseases. A protein-protein interaction (PPI) network was constructed using STRING, and the network topology was analyzed using Cytoscape plugins, CytoHubba and CytoCluster, followed by gene set enrichment analysis using Enrichr-KG. Results: The microarray datasets with accession numbers GSE20966, GSE9624, and GSE1009 for T2D, obesity, and DN, respectively, were pre-processed followed by identification of up-regulated and downregulated genes. These DEGs resulted in identification of 13 common DEGs amongst the diseases. The PPI network constructed using STRING contained 93 nodes and 866 edges followed by identification of 4 hub genes namely AKR1C3, CYP19A1, AKR1D1, and HSD17B3 using Cytoscape plug-ins, CytoHubba and CytoCluster. These 4 hub genes were found to be predominantly involved in steroid hormone biosynthesis pathway. Conclusions: This study reveals that steroid hormones exert a substantial influence on metabolic pathways and play a crucial role in the onset and progression of metabolic disorder such as T2D and its comorbidites. Identification of the molecular factors and mechanisms underlying complex diseases can aid in the design of therapeutic interventions targeting comorbidities.
Keywords: type 2 diabetes (T2D)obesitydiabetic nephropathy (DN)comorbiditymolecular mechanismsdifferential gene expression (DEG)steroid biosynthesis
References
- Dabla PK. Renal function in diabetic nephropathy. World J Diabetes. 2010; 1(2): 48–56.
- Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119.
- Gijsen R, Hoeymans N, Schellevis FG, et al. Causes and consequences of comorbidity: a review. J Clin Epidemiol. 2001; 54(7): 661–674.
- Iglay K, Hannachi H, Joseph Howie P, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016; 32(7): 1243–1252.
- Nowakowska M, Zghebi SS, Ashcroft DM, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019; 17(1): 145.
- Gatineau M, Hancock C, Holman N, Outhwaite H, Oldridge L, Christie A, Ells L. Adult obesity and type 2 diabetes. Public Health England, Oxford 2014: 1–39.
- Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020; 22 Suppl 1: 3–15.
- Standl E, Khunti K, Hansen TB, et al. The global epidemics of diabetes in the 21st century: Current situation and perspectives. Eur J Prev Cardiol. 2019; 26(2_suppl): 7–14.
- Hameed I, Masoodi SR, Mir SA, et al. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World J Diabetes. 2015; 6(4): 598–612.
- Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014; 7: 587–591.
- Samsu N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. Biomed Res Int. 2021; 2021: 1497449.
- Ruze R, Liu T, Zou Xi, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023; 14: 1161521.
- Raman R, Gupta A, Pal SS, et al. Prevalence of Metabolic Syndrome and its influence on microvascular complications in the Indian population with Type 2 Diabetes Mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 14). Diabetol Metab Syndr. 2010; 2: 67.
- Sahrawat TR, Talwar D. Network-Centric Identification of Disease Co-Occurrences: A Systems Biology Approach. Sumerianz J Med Healthc. 2020; 3(11): 103–110.
- Sahrawat T, Dwivedi J. Investigating the Relationship between Diabetes and Alzheimer’s Disease:. Journal of Science and Sustainable Development. 2020; 7(1): 1–11.
- Ni T, Wang N, Mao ZG, et al. Identification of marker genes in diabetic wounds by DNA microarray study. Genet Mol Res. 2013; 12(4): 5348–5355.
- Ali O. Genetics of type 2 diabetes. World J Diabetes. 2013; 4(4): 114–123.
- Tonyan ZN, Nasykhova YA, Danilova MM, et al. Overview of Transcriptomic Research on Type 2 Diabetes: Challenges and Perspectives. Genes (Basel). 2022; 13(7).
- Bima AI, Elsamanoudy AZ, Albaqami WF, et al. Integrative system biology and mathematical modeling of genetic networks identifies shared biomarkers for obesity and diabetes. Math Biosci Eng. 2022; 19(3): 2310–2329.
- Guo M, Dai Y, Jiang L, et al. Bioinformatics Analysis of the Mechanisms of Diabetic Nephropathy Novel Biomarkers and Competing Endogenous RNA Network. Front Endocrinol (Lausanne). 2022; 13: 934022.
- Hu F, Zhang T. Study on risk factors of diabetic nephropathy in obese patients with type 2 diabetes mellitus. Int J Gen Med. 2020; 13: 351–360.
- Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007; 23(14): 1846–1847.
- Zhou DiYi, Mou X, Liu K, et al. prediction and validation of potential therapeutic genes in pancreatic β-cells associated with type 2 diabetes. Exp Ther Med. 2020; 20(5): 60.
- Zheng R, Wang Y, Lyu Zl, et al. Gene Regulatory Network Construction and Key Gene Recognition of Diabetic Nephropathy. 2019 IEEE 7th International Conference on Bioinformatics and Computational Biology ( ICBCB). 2019.
- Zhang S, Wang Bo, Shi J, et al. Network-Based Association Study of Obesity and Type 2 Diabetes with Gene Expression Profiles. Biomed Res Int. 2015; 2015: 619730.
- Kolberg L, Raudvere U, Kuzmin I, et al. gprofiler2 -- an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. F1000Res. 2020; 9.
- Tyner S, Briatte F, Hofmann H. Network Visualization with ggplot2. The R Journal. 2017; 9(1): 27.
- Ritchie ME, Phipson B, Wu Di, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7): e47.
- Heberle H, Meirelles GV, da Silva FR, et al. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics. 2015; 16(1): 169.
- von Mering C, Huynen M, Jaeggi D, et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003; 31(1): 258–261.
- Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11): 2498–2504.
- Chen SH, Chin CH, Wu HH, et al. cyto-Hubba: A Cytoscape plug-in for hub object analysis in network biology. In: 20th international conference on genome informatics. 2009.
- Li M, Li D, Tang Yu, et al. CytoCluster: A Cytoscape Plugin for Cluster Analysis and Visualization of Biological Networks. Int J Mol Sci. 2017; 18(9).
- Evangelista JE, Xie Z, Marino GB, et al. Enrichr-KG: bridging enrichment analysis across multiple libraries. Nucleic Acids Res. 2023; 51(W1): W168–W179.
- Penning TM. AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders. Mol Cell Endocrinol. 2019; 489: 82–91.
- Doig CL, Battaglia S, Khanim FL, et al. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. J Steroid Biochem Mol Biol. 2016; 155(Pt A): 47–55.
- Ostinelli G, Vijay J, Vohl MC, et al. AKR1C2 and AKR1C3 expression in adipose tissue: Association with body fat distribution and regulatory variants. Mol Cell Endocrinol. 2021; 527: 111220.
- Franko A, Berti L, Hennenlotter J, et al. Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes. J Pers Med. 2020; 10(3): 124.
- Svensson PA, Gabrielsson BG, Jernås M, et al. Regulation of human aldoketoreductase 1C3 (AKR1C3) gene expression in the adipose tissue. Cell Mol Biol Lett. 2008; 13(4): 599–613.
- Baddela VS, Sharma A, Michaelis M, et al. HIF1 driven transcriptional activity regulates steroidogenesis and proliferation of bovine granulosa cells. Sci Rep. 2020; 10(1): 3906.
- Nikolaou N, Gathercole LL, Marchand L, et al. AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. Metabolism. 2019; 99: 67–80.
- Su W, Mao Z, Liu Y, et al. Role of HSD17B13 in the liver physiology and pathophysiology. Mol Cell Endocrinol. 2019; 489: 119–125.
- Wang MX, Peng ZG. 17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease. Pharmacol Ther. 2023; 246: 108428.
- Zhang J, Gu W, Zhai S, et al. Phthalate metabolites and sex steroid hormones in relation to obesity in US adults: NHANES 2013-2016. Front Endocrinol (Lausanne). 2024; 15: 1340664.